Upstate Active Clinical Trials

Study Title:

ECOG E5508-Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC.

What is the purpose of the study?

RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Pemetrexed disodium may stop the growth of tumor cells by blocking some enzymes needed for cell growth. It is not yet known whether giving bevacizumab or pemetrexed disodium alone or in combination is more effective in treating non-squamous non-small cell lung cancer.

PURPOSE: This randomized phase III trial is studying bevacizumab and pemetrexed disodium alone or in combination after induction therapy to see how well they work in treating patients with advanced non-squamous non-small cell lung cancer

Upstate Institutional Review Board (IRB) Number:

562684

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Stephen L Graziano, MD

ClinicalTrials.Gov ID:

NCT01107626

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Linda L Spillett, CCRP
Phone: 315-464-8237
Email: spilletl@upstate.edu

Return to Previous Page || Search Again